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Background. In 2005, pneumonia practice guidelines recommended broad-spectrum antibiotics for patients
with risk factors for nosocomial pathogens. The impact of these recommendations on the ability of providers to
match treatment with nosocomial pathogens is unknown.
Methods. Among hospitalizations with a principal diagnosis of pneumonia at 128 Department of Veterans
Affairs medical centers from 2006 through 2010, we measured annual trends in antibiotic selection; initial blood
or respiratory cultures positive for methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa,
and Acinetobacter species; and alignment between antibiotic coverage and culture results for MRSA and P. aerugi-
nosa, calculating sensitivity, speciﬁcity, and diagnostic odds ratio using a 2 × 2 contingency table.
Results. In 95 511 hospitalizations for pneumonia, initial use of vancomycin increased from 16% in 2006 to 31% in
2010, and piperacillin-tazobactam increased from 16% to 27%, and there was a decrease in both ceftriaxone (from 39%
to 33%) and azithromycin (change from 39% to 36%) (P < .001 for all). The proportion of hospitalizations with cultures
positive forMRSA decreased (from 2.5% to 2.0%; P < .001); no change was seen for P. aeruginosa (1.9% to 2.0%; P = .14)
orAcinetobacter spp. (0.2% to 0.2%; P = .17). For both MRSA and P. aeruginosa, sensitivity increased (from 46% to 65%
and 54% to 63%, respectively; P < .001) and speciﬁcity decreased (from 85% to 69% and 76% to 68%; P < .001), with no
signiﬁcant changes in diagnostic odds ratio (decreases from 4.6 to 4.1 [P = .57] and 3.7 to 3.2 [P = .95], respectively).
Conclusions. Between 2006 and 2010, we found a substantial increase in the use of broad-spectrum antibiotics for
pneumonia despite no increase in nosocomial pathogens. The ability of providers to accurately match antibiotic coverage
to nosocomial pathogens remains low.
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Pneumonia is the leading infectious cause of death in
the United States, with 1.1 million hospitalizations
annually [1, 2]. Optimal treatment involves selecting
an empiric antibiotic regimen (before obtaining results
of microbiologic tests) that targets pathogens while
avoiding drugs that extend the spectrum of coverage
to organisms not causing infection. In 2005, the Infec-
tious Disease Society of America and the American
Thoracic Society introduced the classiﬁcation of health-
care-associated pneumonia (HCAP), recommending
empiric coverage of methicillin-resistant Staphylococcus
aureus (MRSA) and Pseudomonas aeruginosa in pa-
tients meeting criteria for recent prior healthcare
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exposure [3]. The 2007 update of the community-acquired pneu-
monia guidelines further emphasized that patients with risk factors
for HCAP should be treated with broad-spectrum antibiotics [4].
Efforts to improve pneumonia outcomes have reinforced this rec-
ommendation through dissemination of guidelines, performance
measures by Medicare, and public health initiatives [5, 6].
Since the introduction of the HCAP classiﬁcation, concerns
have been raised that the risk factors for HCAP are too broad,
driving excessive antibiotic use rather than improving providers’
ability to identify patients truly at risk for nosocomial pathogens
[7]. It is unknown how these recommendations have impacted
providers’ ability to match empiric broad-spectrum antibiotic
treatment to patients at risk for nosocomial pathogens.
The US Department of Veterans Affairs (VA) health system
uses a universal electronic health record, with standardized
medication and culture data. This allows us to examine trends
in initial antibiotic selection and microbiology at the patient
level across a large health system. Associations between MRSA
cultures and anti-MRSA treatment in infection-related hospital-
izations were measured previously [8, 9]. Using the same data
set in the current study, we aimed to evaluate annual trends
in initial antibiotic selection and nosocomial pathogen identiﬁ-
cation across the entire VA medical system and to examine
trends in the match between initial antibiotics and culture re-
sults. We tested the hypothesis that the match between broad-
spectrum antibiotic use and culture results would increase in
the years after the guidelines were disseminated.
METHODS
Setting
This study was performed with data collected from VA medical
centers from 1 January 2006 through 31 December 2010 [10].
We included all facilities with ≥10 operational acute care beds
and complete electronic medication administration records.
Data were accessed and analyzed using the VA Informatics
and Computing Infrastructure [11].
Subject Selection
During the study period, we selected all hospitalizations of pa-
tients ≥18 years of age in acute medical, surgical, or neurolog-
ical wards and intensive care units (ICUs). We then identiﬁed
hospitalizations with a principal International Classiﬁcation of
Disease, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) [12]
code consistent with pneumonia (codes 481–486), similar to
other studies [13, 14], excluding those with ICD-9-CM codes
for viral pneumonia and inﬂuenza (480.0–480.9 and 487.0–
488.19). To evaluate whether diagnostic coding for pneumonia
was consistent during the study period relative to other diseases,
we also identiﬁed all hospitalizations with principal ICD-9-CM
codes consistent with sepsis (038.x, 995.91, 995.92, and 785.52),
skin and soft-tissue infections (680–686), and genitourinary in-
fections (590, 595.0, 597, 598.0, 599.0, 614.0, 614.1–5, 616.0,
616.1, 616.3, and 616.4).
Measurements: Antibiotic Use
We measured antibiotic use using bar code medication adminis-
tration, which records all medications administered to hospitalized
patients [15]. Because we were interested in the use of antibiotics
before culture results were available, initial antibiotic therapy was
deﬁned as the systemic administration of at least 1 dose of an
antibiotic within the ﬁrst 2 calendar days of hospitalization. We
calculated the proportion of hospitalized patients receiving antibi-
otics for pneumonia. We combined respiratory ﬂuoroquinolones
(moxiﬂoxacin, levoﬂoxacin, and gatiﬂoxacin), macrolides (azithro-
mycin, clarithromycin, and erithromycin), and tetracyclines (dox-
ycycline and tetracycline) into single categories.
Because multiple antibiotics may be administered concurrently
and we wanted to detect breadth of coverage for pneumonia
pathogens, we then classiﬁed antibiotics with activity against
the following pathogen types: atypical organisms (respiratory ﬂu-
oroquinolone, macrolide, or tetracycline), standard organisms
(guideline-concordant coverage with either an antipneumococcal
or nonantipseudomonal β-lactam [listed in the “Results” section]
plus a macrolide or a respiratory ﬂuoroquinolone), MRSA
(vancomycin or linezolid), and single coverage for P. aeruginosa
(piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime,
cefepime, meropenem, doripenem, imipenem, or aztreonam).
Because the guidelines from the Infectious Disease Society of
America and the American Thoracic Society call for combination
therapy to ensure coverage of P. aeruginosa in selected patients,
an additional category was created requiring the combination of
single coverage with an antipseudomonal ﬂuoroquinolone (cipro-
ﬂoxacin or levoﬂoxacin) or aminoglycoside, consistent with
guideline recommendations [4].
Measurements: Microbiologic Data
We accessed microbiologic data on all cultures drawn at any time
during each hospitalization, which were standardized into Sys-
temized Nomenclature of Medicine (SNOMED-CT) format
[16]. Organism data were included if susceptibility testing was
performed. Initial positive cultures were identiﬁed for 3 common
nosocomial pathogens associated with pneumonia—MRSA,
P. aeruginosa, and Acinetobacter spp.We classiﬁed culture source
into blood, respiratory (sputum, endotracheal aspirate, bronchio-
lar lavage, wash, or biopsy, or pleural ﬂuid), or “other,” which in-
cluded wound and urine cultures. Because we were interested in
identifying pathogens that were present at hospital admission
rather than acquired during a hospitalization, we deﬁned a pos-
itive initial pneumonia-related culture as any positive result that
had been obtained during the ﬁrst 2 calendar days of the hospi-
talization, from either blood or respiratory sources.
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Statistical Analysis
To assess providers’ ability to accurately differentiate patients at
risk for nosocomial pathogens, we examined trends in the align-
ment between the selection of initial antibiotics and recovery of
organisms from microbiologic cultures. Our assessment is thus
similar to the evaluation of accuracy of a diagnostic test (Table 1).
A “true-positive” was deﬁned as the match between initial treat-
ment and positive growth of the targeted organism in culture. A
“true-negative” was deﬁned as the absence of coverage for a path-
ogen and lack of recovery of the corresponding organism. For ex-
ample, a MRSA true-positive hospitalization was one during
which initial anti-MRSA therapy was administered and a pneu-
monia-related culture was positive for MRSA, and a MRSA true-
negative hospitalization one during which no anti-MRSA therapy
was administered and noMRSA-positive cultures were identiﬁed.
Sensitivity was deﬁned as the proportion of admitted patients
with MRSA-positive cultures who received anti-MRSA therapy,
and speciﬁcity the proportion without positive MRSA cultures
who did not receive such therapy.
The diagnostic odds ratio (DOR) was calculated as a compos-
ite measure of performance to reﬂect both sensitivity and spe-
ciﬁcity [17]. The DOR equals the positive likelihood ratio
divided by the negative likelihood ratio, or (Sensitivity · Specif-
icity)/([1− Sensitivity] · [1− Speciﬁcity]) (Table 1). The greater
the DOR, the greater the overall sensitivity and speciﬁcity, and
overall matching between culture and coverage, that occurred.
For example, sensitivity and speciﬁcity of 0.50 would result in
a DOR of 1; sensitivity and speciﬁcity of 0.75, a DOR of 9. To
measure trends in the coverage-culture concordance for MRSA
or P. aeruginosa, we calculated annual sensitivity, speciﬁcity,
and the DOR for each year, and the difference in the proportion
of true-positive cases and false-positive cases from 2006 to 2010.
We analyzed temporal trends in antibiotic use, nosocomial
pathogens, and alignment between coverage and culture results
using logistic generalized estimating equation models, which
took facility-level correlations into consideration. Calendar
year was added as the single independent variable. All statistical
analyses were performed using Stata (version 12.0; StataCorp)
and R (http://cran.r-project.org) software. The study was con-
ducted with approval from the University of Utah Institutional
Review Board and the Salt Lake City VA Human Research Pro-
tection Program.
RESULTS
Temporal Trends: Diagnosis and Demographics
Of a total of 2.4 million hospitalizations at 128 facilities meeting
our study criteria, 95 511 (3.9%) had a principal diagnosis of
pneumonia during the study period. The proportion of hospital-
izations for pneumonia remained stable over time, in contrast to
the increase seen in sepsis diagnoses (Figure 1). The median age
of patients hospitalized for pneumonia was 71 years (mean, 70
years; interquartile range, 61–81 years), and their median length
of stay was 4 days (mean, 6 days; interquartile range, 3–7 days).
Of these patients, 12% were initially admitted to the ICU.
Antibiotic Use
Antibiotic use for veterans hospitalized with pneumonia shifted
signiﬁcantly during the 5-year period (Figure 2). Initial use of
vancomycin increased from 16% to 31% (P < .001), use of piper-
acillin-tazobactam increased from 16% to 27% (P < .001), and
use of ceftriaxone and azithromycin decreased (P < .001). Use
of macrolides (azithromycin in 99.5%) decreased from 39.5%
to 36.0% (P < .001). Overall, antipseudomonal coverage and
MRSA therapy increased, and a signiﬁcant decline in initial ther-
apy with standard and atypical coverage was observed (Figure 3;
P < .001 for all). The proportion of hospitalizations with initial
double antipseudomonal coverage, though low, also increased
signiﬁcantly during the study period (from 5% to 11%;
Figure 1. Proportion of hospitalized veterans with principal infectious di-
agnoses, 2006–2010 (total number hospitalized, 2.4 million).
Table 1. MRSACulture-Coverage Matching Analysis Characterized
in a 2 × 2 Tablea
Culture MRSA Positive
MRSA Coverage Given
No Yes
Yes FN decision TP decision
No TN decision FP decision
Abbreviations: FN, false-negative; FP, false-positive; MRSA, methicillin-
resistant Staphylococcus aureus; TN, true-negative; TP, true-positive.
a Measures of performance were defined as follows:
Sensitivity (Se) = TP/(TP + FN); Specificity (Sp) = TN/(TN + FP); Positive
likelihood ratio (PLR) = Se/(1 − Sp); Negative likelihood ratio (NLR) = 1 − Se/
(Sp); and Diagnostic odds ratio = (TP · TN)/(FN · FP), or PLR/NLR.
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P < .001). Overall 8.1% of hospitalized patients did not receive
any guideline-concordant antibiotics. The most common antibi-
otics used in these hospitalizations were ciproﬂoxacin (single
therapy), clindamycin, and trimethoprim-sulfamethoxazole.
We found a small, nonsigniﬁcant increase in hospitalizations
without guideline-concordant therapy during the study period
(from 7.7% in 2006 to 8.3% in 2010; P = .055).
Microbiology and Culture-Coverage Concordance
Overall, 84.5% of pneumonia hospitalizations had documenta-
tion of ≥1 culture obtained from a blood or respiratory speci-
men within 2 days of admission. Respiratory cultures were less
frequently collected (34.0% of hospitalization) than blood cul-
tures (81.7% of hospitalizations). We found a small increase in
blood culture collection over time (79.7% in 2006 to 82.1% in
2010, P < .001) and no signiﬁcant change in proportion of hos-
pitalizations with respiratory cultures obtained.
The overall proportions of hospitalizations with positive ini-
tial cultures were 2.2% for MRSA, 2.0% for P. aeruginosa, and
0.2% for Acinetobacter spp. A signiﬁcant decline in MRSA was
observed, whereas P. aeruginosa and Acinetobacter spp. re-
mained stable (Figure 4). Of the positive cultures, 88% positive
for MRSA, 96% for P. aeruginosa, and 76% for Acinetobacter
spp. were from a respiratory source.
Figure 5 displays annual trends in sensitivity, speciﬁcity, and
DORs for the alignment between antibiotic coverage and cul-
ture results for MRSA and P. aeruginosa. For both pathogens,
sensitivity increased and speciﬁcity decreased substantially.
The resulting annual DORs for both pathogens demonstrated
no signiﬁcant change from 2006 to 2010 (MRSA, from 4.6 to
4.1 [P = .57]; P. aeruginosa, 3.1 to 2.8 [P = .95]). The proportion
of true-positive cases increased slightly for both pathogens
(from 1.1% to 1.3% for MRSA and from 0.9% to 1.2 for P. aer-
uginosa), but the proportion of false-positive cases increased
signiﬁcantly (from 15.0% to 30.6% for MRSA and from
21.0% to 33.6% for P. aeruginosa; P < .001 for both).
DISCUSSION
The selection of empiric antibiotics for pneumonia is challeng-
ing, with consequences to both individual patients and the public
health that are difﬁcult to weigh. Because current microbiolo-
gic tests are imperfect, whether or not a patient is given broad-
spectrum antibiotics depends on a provider’s estimation of the
Figure 2. Five-year trends in initial antibiotic use for hospitalized pa-
tients with pneumonia, 2006–2010. Error bars represent 95% conﬁdence
intervals.
Figure 3. Trends in antimicrobial coverage for hospitalized patients with
pneumonia in 2006–2010. Error bands represent 95% conﬁdence intervals,
For coverage, any atypical coverage includes respiratory ﬂuoroquinolones,
macrolide, and tetracycline; standard or guideline-concordant coverage
includes nonpseudomonal β-lactam plus a macrolide and respiratory
ﬂuoroquinolone; nonpseudomonal β-lactam coverage includes ampicillin,
amoxicillin, ampicillin-sulbactam, amoxicillin-clavulanate, cefuroxime,
cefotaxime, ceftriaxone, ceftizoxime, ceﬁxime, cefpodoxime, ceftibuten,
cefdinir, and ertapenem; single Pseudomonas coverage includes piperacil-
lin-tazobactam, ticarcillin-clavulanate, ceftazidime, cefepime, meropenem,
doripenem, imipenem, aztreonam, and aminoglycoside; methicillin-resistant
Staphylococcus aureus (MRSA) coverage includes vancomycin and linezolid;
and double Pseudomonas coverage includes any 2 of the above or 1 of the
above plus ciproﬂoxacin or levoﬂoxacin.
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probability of resistant pathogens as well as his/her threshold for
treatment. When a causative pathogen is uncertain, as is the case
for most patients with pneumonia, providers must perform the
difﬁcult task of weighing the risks and beneﬁts of overtreatment
versus undertreatment.
Our 5-year study of over 95 000 hospitalizations for pneumonia
across the VA system is, to our knowledge, the ﬁrst to examine
trends in antibiotic use and culture results together on a large
scale. We found a substantial shift toward broad-spectrum agents.
During the same time period, we found no increase in initial cul-
tures positive for the 3 most common nosocomial pathogens.
The shift in antibiotic use to broad-spectrum agents for
pneumonia is not unique to the VA system. Berger et al [18] re-
viewed nationwide antibiotic practices in the United States and
found similar trends for hospitalized non-ICU patients with
pneumonia . The decrease seen in MRSA pneumonia has also
been suggested in other studies during the same time period
[19–22], in contrast to the period of 2000–2005, when there
was a rise in diagnostic coding for MRSA [23]. The prevalence
of P. aeruginosa among hospitalized patients with pneumonia
has also been reported to be stable [20, 22].
By combining antibiotic administration and culture data, we
examined whether the observed trends in antibiotic use observed
resulted in a change in clinicians’ ability to match broad-spectrum
antibiotic coverage to cultures for nosocomial pathogens. The in-
crease in broad-spectrum antibiotics was comparable in patients
with and without positive cultures, and the match between treat-
ment and pathogen remained unchanged.
These results suggest that the shift toward broad-spectrum
antibiotics reﬂects a change in the threshold for treatment rather
than a response to increased prevalence or enhanced ability to
identify patients at risk for resistant organisms. Increased recog-
nition of HCAP risk factors, driven largely by dissemination of
guidelines, probably modiﬁed clinicians’ perception of risk.
This change was not accompanied by an improved ability to
determine which patients actually have MRSA or P. aeruginosa
infection. Although the increase in broad-spectrum antibiotics
did result in an increase in coverage of more patients with nos-
ocomial pathogens, this came at the cost of treating many pa-
tients unnecessarily with broad-spectrum antibiotics, and more
than a third of patients with positive cultures still failed to re-
ceive appropriate initial coverage.
Our study was not designed to determine whether the shift in
antibiotic use had a positive or negative impact on clinical out-
comes. Because patients meeting HCAP criteria tend to have
higher mortality risk and risk of nosocomial pathogens, it was
thought that the observed increase in mortality rates may be due
to inadequate therapy [24]. However, since the adoption of the
HCAP deﬁnition, studies examining clinical outcomes have
found either no improvement or even an increase in mortality
rates associated with the use of broad-spectrum antibiotics in
this group [25–29]. A single study suggested a possible beneﬁt
to broader-spectrum therapy when applying a more reﬁned risk
assessment [30]. In our study, as the proportion of patients re-
ceiving broad-spectrum antibiotics increased, the proportion
receiving standard therapies, including coverage for atypical
pneumonia pathogens, decreased. This raises concern that ex-
cessive use of broad-spectrum antibiotics could promote under-
use of more standard therapies and failure to cover more
common pneumonia pathogens.
Currently, clinicians have few ways to improve their ability to
match antibiotics with likely pathogens for pneumonia. Reﬁning
and validating the clinical risk factors for nosocomial pathogens
has been a major recent focus of research [31, 32], although accu-
racy in predicting resistant pathogens remains low [32–35]. The
development of new accurate rapid diagnostic tests as well as
more consistent use of tests currently available may increase our
yield of pathogens and include initial respiratory cultures (docu-
mented in only 32% of our patients, although the majority of pos-
itive cultures were identiﬁed from a respiratory source) and
MRSA surveillance (the VA’s system-wide program has demon-
strated high negative predictive value compared with cultures
for patients with pneumonia) [9] In lieu of rapid identiﬁcation
and reliable clinical risk assessment, comparative effectiveness re-
search evaluating the consequences of conservative versus aggres-
sive antibiotic coverage strategies (ie, withholding broad-spectrum
therapy until cultures result vs tailoring antibiotics after cultures)
will also improve our ability to base our empiric antibiotic selec-
tion on actual risks.
Figure 4. Proportion of hospitalized patients with pneumonia with
cultures positive for Pseudomonas aeruginosa, methicillin-resistant
Staphylococcus aureus (MRSA), or Acinetobacter spp. within 2 days of
hospitalization.
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We recognize several limitations to our study. We used admin-
istrative data that relied on principal diagnostic codes to identify
cases of pneumonia, and we did not identify patient-level clinical
factors. Our results therefore may have been affected by unmea-
sured changes in clinical population or diagnostic coding practices.
Deﬁning the study population using principal diagnoses for
pneumonia plus sepsis and respiratory failure with pneumonia
as secondary may have provided more cases of severe pneumo-
nia in the later years and identiﬁed more hospitalizations with
broad-spectrum antibiotic use and positive cultures. However,
the profound rate of increase in both piperacillin-tazobactam
and vancomycin use suggests that providers have decreased
their threshold for usage in similar patients. We did not report
trends in more typical pneumonia pathogens or less common
Figure 5. Trends in match between coverage and culture for methicillin-resistant Staphylococcus aureus (MRSA) (A) and Pseudomonas aeruginosa (B).
Error bands represent 95% conﬁdence intervals. Sensitivity was deﬁned as the proportion of patients with MRSA- or Pseudomonas-positive cultures who
received anti-MRSA or antipseudomonal therapy; speciﬁcity, the proportion without positive cultures who did not receive such therapy. The diagnostic odds
ratio is a composite measure of performance reﬂecting both sensitivity and speciﬁcity (see “Statistical Analysis” section and Table 1).
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resistant pathogens, such as those carrying extended-spectrum
β-lactamases, for which broad-spectrum antibiotics are indicated.
At the individual level, it is impossible to determine the appro-
priateness of broad-spectrum antibiotic use for any given patient
from our study. Rather, we aimed to develop a population metric
that is informative about thresholds for decision making.
Clinicians continue to be challenged by the dilemma of wheth-
er to use broad-spectrum antibiotics in the treatment of pneumo-
nia. Unnecessary use of broad-spectrum antibiotics carries
substantial risk, both to individual patients and to public health.
So does undertreatment of resistant pathogens. Given the raised
awareness of antimicrobial resistance prompted by practice
guidelines, it is not surprising that providers at the VA, as in other
systems, have lowered their threshold for using broad-spectrum
antibiotics since the guidelines were disseminated. Our study
suggests, however, that even with a higher-caliber shotgun, we
are still missing the mark. Our study supports an urgent need for
research on the impact of this change in threshold on outcomes
and better strategies to identify patients who would truly beneﬁt
from broad-spectrum antibiotics. Without better evidence that
helps providers weigh the risks and beneﬁts of broad-spectrum
antibiotic use for their patients with pneumonia, we are likely
to see continued excessive use of this important resource.
CONCLUSIONS
We found a substantial increase in the use of both vancomycin
and piperacillin-tazobactam from 2006 to 2010 in a national
population of 95 511 hospitalized veterans with pneumonia,
with no increase in initial positive cultures for MRSA, P. aeru-
ginosa, or Acinetobacter spp. Although providers’ thresholds for
broad-spectrum antibiotic use have decreased, the ability to ac-
curately match antibiotic coverage to culture results for MRSA
and P. aeruginosa has not improved.
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